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1   PROTEASE ACTIVATED RECEPTOR 
 
Seven transmembrane G protein coupled receptors (GPCRs) are the largest group of 
membrane receptors in mammalian systems and many of them are target of drugs which are 
currently in clinical use.  Among this receptor family, protease-activated receptors (PARs) are 
a subset which have a unique mechanism of activation.  In fact, rather than being activated by 
simple ligand occupancy, they are activated enzymatically through proteolysis by enzymes of 
the serine protease family (Macfarlane et al., 2001).  The proteolytic cleavage occurs at 
specific sites within their N-terminal region, thereby exposing novel N-termini, and the 
‘tethered ligand’ then folds back onto the extracellular loop II of the receptor, resulting in 
activation.   
PARs are expressed in various tissues and cell types, such as cardiomyocytes, platelets, 
fibroblasts, endothelial cells and cells of the gastrointestinal tract and lung.  Activation of 
these receptor types is involved in various cellular responses associated with haemostasis, 
inflammation and cell proliferation, thus making them attractive targets for the therapeutic 
treatment of several diseases including thrombosis, atherosclerosis, cancer metastasis and 
inflammation.  
There are four PARs encoded by distinct genes in the mammalian genome.  The 
prototype of this GPCR subfamily is PAR1 which was discovered in 1991 (Vu et al., 1991; 
Rasmussen et al., 1991) and transmits cellular response to thrombin, the main effector 
protease of the coagulation cascade.  Soon after, other three members of the subfamily were 
identified which include PAR2 (Nystedt et al., 1995), the trypsin-activated receptor, and two 
other thrombin-activated receptors, PAR3 (Ishihara et al., 1997) and PAR4 (Xu et al., 1998).  
Whereas cleaved PAR4 is able to activate diverse signaling pathways the ability of activated 
PAR3 to signal on its own is not completely clear.  PAR1 seems to act as a cofactor for 
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thrombin-mediated activation of PAR4 (Nakanishi-Matsui et al., 2000) and may also signal as 
part of a PAR1-PAR3 heterodimer (McLaughlin et al., 2007).  Other proteases besides trypsin 
for PAR2 and thrombin and trypsin for PAR1 and PAR4 can activate these receptors (Soh et 
al., 2010) as well as synthetic peptides that mimic the first six amino acids of the newly 
formed N-terminus and act as soluble ligands in the absence of receptor proteolysis.  Some 
PAR agonist peptides (PAR-APs) activate more than one PAR at concentrations in the 
micromolar range, as compared with nanomolar potencies of the proteases themselves.  
 
 
1.1 Mechanism of activation by cell-surface proteolysis 
1.1.1 Proteases cleavage and exposure of tethered ligand domains 
 
The general mechanism by which proteases cleave and activate PARs is the same: 
proteases cleave at specific sites within the extracellular amino terminus of the receptors.  
This cleavage exposes a new amino terminus that serves as a tethered ligand domain, which 
binds to conserved regions in the second extracellular loop of the cleaved receptor, resulting 
in the initiation of signal transduction.  There is no known function of the amino-terminal 
fragment of the receptor that is removed by proteolysis.  The mechanism by which thrombin 
activates PAR1 has been investigated in detail.  Thrombin cleaves PAR1 at R
41↓S42FLLRN in 
the N-terminal region, to expose the tethered ligand NH2-SFLLRN, which binds and activates 
the cleaved receptor, resulting in signal transduction.  Several observation support this 
mechanism of activation.  Mutation of the cleavage site prevents thrombin cleavage and 
signalling, indicating the importance of this site for PAR1 activation (Vu et al., 1991).  A 
synthetic peptide (S
42
FLLRN) that mimics the tethered ligand domain directly activates intact 
PAR1, without the requirement for hydrolysis by thrombin.  Such synthetic agonists are useful 
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tools for investigating PAR functions.  Similar observations indicate that trypsin cleaves 
PAR2 at R
34↓S35LIGKV to reveal the amino-terminal tethered ligand SLIGKV in humans 
(Nystedt et al., 1995).  Synthetic peptides corresponding to the tethered ligand domain 
SLIGKV activate PAR2 without the need for receptor cleavage.  PAR3 is cleaved by thrombin 
at K
38↓F39RGAP and mutation of the cleavage site to one that would be resistant to thrombin 
prevents its activation (Ishihara et al., 1997).  This cleavage exposes a new amino terminus 
(TFRGAP) that may interact with the receptor as a tethered ligand.  However, in marked 
contrast to PAR1, PAR2 and PAR4, synthetic peptides corresponding to this putative tethered 
ligand do not activate PAR3.  The reason for this discrepancy is unknown, although 
differences in affinity, steric hindrances and the possibility that cleavage releases 
conformation of the receptor constrained by the uncleaved amino terminal region could 
explain these unexpected results.  Another unexpected observation is that mouse PAR3 is 
unable to signal when expressed alone, without other PARs (kahn et al., 1998).  Thrombin 
and trypsin cleave PAR4 at R
47↓G48YPGQV and peptides corresponding to the tethered ligand 
domain GYPGQV can directly activate PAR4 (kahn et al., 1998).  Mutation of the cleavage 
site prevents activation by thrombin and trypsin but not by the synthetic peptides, which 
confirms the importance of the proteolytic cleavage for receptor activation.  
 
 
1.1.2 Facilitation of PARs cleavage and activation by protease binding 
 
Thrombin can activate PAR1 and PAR3, by a two-step mechanism: first the protease 
binds and then it cleaves the receptor.  The process of binding and activation has been most 
thoroughly studied for thrombin and PAR1 (Vu et al., 1991).  In addition to containing the 
tethered ligand, the PAR1 exodomain also harbors a hirudin-like (Hir) sequence element, 
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K
51
YEPF
55
, that is essential for high-affinity interactions with thrombin.  This charged 
domain is distal to the thrombin cleavage site and binds to an anion binding site on thrombin, 
thereby temporarily concentrating the protease at the surface of the receptor.  This negatively 
charged region of PAR1 resembles a domain of the leech anticoagulant hirudin, which inhibits 
thrombin by binding its anion site.  The importance of the hirudin-like domain is emphasized 
by the finding that its deletion markedly diminishes the capacity of thrombin to activate PAR1 
whereas substitution of this region with the corresponding domain of hirudin allows a full 
recovery of activity.  Steady-state kinetic studies using soluble full-length PAR1 exodomains 
showed that the initial binding of the Hir sequence of PAR1 with exosite I is essential for 
rapid association to thrombin. In a second and rate-limiting step, the exosite I-bound Hir motif 
facilitates the productive interaction of the PAR1 cleavage sequence to the active site of 
thrombin.  The subsequent irreversible steps of peptide bond cleavage are rapid and 
allosterically enhanced by the presence of the docked Hir sequence.  Following cleavage, 
thrombin remains associated with the C-terminal portion of the PAR1 exodomain via this 
high-affinity Hir sequence.  Complementary studies with an array of thrombin active site and 
exosite mutants further demonstrated the importance of the thrombin exosite I for efficient 
binding and cleavage of PAR1 peptides.  Docking studies of the PAR1 exodomain Hir motif to 
exosite I of thrombin reveals that the active site of thrombin is readily accessible to another 
large macromolecular substrate.  This supports the notion that an additional role of the PAR1 
Hir sequence is to tether thrombin to the platelet surface and assist in the cleavage of other 
nearby platelet receptors that lack a high-affinity Hir-like sequence.  
Adjacent to the Hir-motif is an anionic E57DEE60 cross-cluster that splays outward 
from the exodomain where it is available for electrostatic interactions with the positively 
charged thrombin exosite-1.  A hydrophobic scaffolding residue, Trp
56
, anchors both the 
adjacent Hir and EEDE motifs by making numerous contacts with Pro
54
, Phe
55
, Glu
57
, Asp
58
, 
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Leu
66
 and Thr
67
.   Kinetic analyses of soluble PAR1 exodomains showed that the presence of 
Trp
56
 enhances the affinity of the adjacent Hir sequence for exosite I of thrombin by 11-fold.  
The N-terminal tethered ligand forms an intramolecular complex with a region located 
in the C terminus of the PAR1 exodomain that was confirmed to be an authentic ligand 
binding site LBS-1 (P85AFIS89) in full-length receptor.  
 
 
PAR3 also contains a hirudine-like site (FEEFP) that is distal to the thrombin cleavage 
site, which interacts with thrombin (Ishihara et al., 1997).  PAR4, in contrast to the other 
thrombin receptors, lacks a hidurin-like binding site for thrombin (Xu et al., 1998).  Protease 
binding site have not been identified for PAR2. 
 
 
1.1.3 Functional interactions between PARs 
 
A common theme of signalling by GPCRs is that there are frequently several different 
receptors for a single ligand and often several ligands for one receptor.  Thus thrombin can 
activate PAR1, PAR3 and PAR4, with different potencies and trypsin, tryptase and certain 
coagulant factors can activate PAR2.  This complexity becomes particularly interesting 
because PARs are frequently coexpressed and interactions between receptors in the same cell 
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can have important functional consequences.  Human platelets express two thrombin 
receptors, PAR1 and PAR4.  There are marked differences in the mechanisms of activation 
and inactivation of these receptors that have important consequences for thrombin signalling 
to platelets. As previously explained, PAR1, in contrast to PAR4, responds to low 
concentrations of thrombin and its responses are rapidly shut-off, probably as a result of 
phosphorylation of residues in the carboxy terminus and uncoupling from G proteins while 
PAR4 responses are sustained and desensitize slowly (Kahn et al., 1999).  The coexpression 
of two receptors with different potencies and kinetics of desensitization may have important 
functional consequences.  Thus, in human platelets PAR1 mediates rapid and transient 
increases in intracellular calcium concentration ([Ca
2+
]i) to low concentrations of thrombin 
whereas PAR4 mediates delayed and sustained increases in [Ca
2+
]i to higher thrombin 
concentrations (Covic et al., 2000).  This prolonged signal is important for the late phases of 
platelet aggregation. Similar dual receptor system probably exist on other cells with important 
functional consequences.  
In some instances, protease binding to one receptor can facilitate cleavage of another 
receptor that is expressed on the same cell.  This appear to be the situation for PAR3 and 
PAR4 on murine platelets.  PAR3 acts as a cofactor for PAR4 in murine platelets where it 
facilitates activation of PAR4 by low concentrations of thrombin.  The hirudin-like site of 
PAR3 binds and concentrates thrombin at the cell surface, and thereby promotes thrombin 
cleavage of PAR4.  At high concentrations, thrombin can directly cleave and activate PAR4, 
even though it lacks a thrombin binding domain.  
GPCRs can form homodimers and heterodimers with important consequences for signal 
transduction.  Although the principal mechanism of PAR activation is intramolecular, there 
are several examples of intermolecular interactions between different PAR molecules.  
Intermolecular signalling, by which a cleaved receptor can activate an uncleaved receptor, 
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was first demonstrated for PAR1 (Chen et al., 1994) when in a reconstituted system was 
shown that is possible for the tethered ligand of cleaved PAR1 to activate an uncleaved 
receptor.  There is also evidence of intermolecular signalling between different PARs. 
Peptides corresponding to the tethered ligand of PAR1 (SFLLRN) can also activate PAR2, but 
not vice versa (Blackhart et al., 1996).  Several results suggest that the tethered ligand domain 
of PAR1 can interact with uncleaved PAR2 to transduce the signal (O’Brien et al., 2000).  
Recently it has been demonstrated that PAR1/PAR3 heterodimers are formed constitutively in 
endothelial cells and the activated dimeric complex induces distinct signalling involving the 
selective coupling to Gα13 as compared with the PAR1/PAR1 homodimer.  The ability of 
PAR1 to form heterodimers with PAR3 indicates that this heterodimer is formed under 
physiological conditions and could be implicated in endothelial barrier dysfunctions 
(McLaughlin et al., 2007).  This novel form of intermolecular signalling between different 
PARs clearly requires the close association of receptors at the cell surface, which could be 
influenced by levels of expression or by anchoring proteins that may affect  mobility of 
receptors in the membrane.  
 
 
1.2 Signal transduction from protease activated receptors 
1.2.1 Structure-activity relations of tethered ligand domains 
 
The observation that synthetic peptides corresponding to the tethered ligand domain of 
PAR1 are agonists for the receptor without the need for proteolysis had three important 
consequences.  First, it enabled the use of syntethic peptides as probes for PAR function 
thereby avoiding the sole use of proteases, which have many biological effects not related to 
PARs.  These APs are now widely used to investigate the physiological functions of PARs in 
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vitro and in vivo.  Second, it permitted convenient structure activity studies of the tethered 
ligand domain through functional analyses of synthetic peptides (Maryanoff et al., 2001).  
Such studies have provided important information about critical residues of the tethered 
ligand and facilitated the development of more selective agonists (Hollenberg et al., 1997).  
Third, analogues of the APs have been used as templates for the development of antagonists 
of PAR1 (Andreade-Gordon et al., 1999).  However, there are certain limitations to the use of 
APs as PAR agonists.  Unfortunately, APs are weak agonists compared with proteases, often 
requiring concentrations in excess of 1 µM to activate most PARs.  The low potency of APs is 
mostly attributed to the inefficient presentation of these soluble peptides to the binding 
domains of the receptor compared with the tethered peptide.  In addition, these peptides are 
readily inactivated by proteolysis.  Because APs are used at such high concentrations, they 
may have nonspecific effects that are unrelated to PAR activation.  The use of control 
peptides, such as inactive scrambled peptides or reversed sequences, is thus essential, 
although these too can have activity.  In addition, APs are not always specific for a particular 
PAR; for example, the PAR1-AP SFLLRN also activates PAR2 (Blackhart et al., 1996).  
Replacement of Ser
1
 with Thr
1
 (corresponding to the sequence in Xenopus PAR1) in 
PAR1-AP generates an agonist TFLLRN that is selective for PAR1 and that does not activate 
PAR2. 
 
 
1.2.2 Activation of multiple signaling cascades 
 
Activated PAR1 and PAR2 couple to multiple heterotrimeric G-protein subtypes 
including Gi, Gq and G12/13 (Coughlin, 2005; Soh et al., 2010), whereas PAR4 couples to Gq 
and G12/13 activation.  In doing so, PAR1 and PAR2 also activate numerous effector pathways 
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in most cell types including mitogen-activated protein kinases (MAPKs), various Rho kinase 
and phospholipase C (PLC) isoforms, inositol lipid signaling and mobilization of intracellular 
Ca
2+
 (Macfarlane et al., 2001).  Gαq stimulates phospholipase C to produce inositol 
trisphosphate (IP3), which mobilizes intracellular Ca
2+
, and diacylglycerol (DAG) activating 
protein kinase C (PKC).  Together, Ca
2+
 and PKC activate numerous downstream pathways, 
including Ca
2+
-regulated protein kinases and mitogen-activated protein (MAP) kinases.  
Gα12/13 plays a major role in the control of cell shape and migration through interaction with 
Rho guanine-nucleotide exchange factors (Rho-GEF).  Gαi proteins inhibit adenylyl cyclase 
and suppress formation of cAMP.  Gβγ subunits of heterotrimeric G proteins couple PAR1 to 
many other pathways, notably activation of phosphatidylinositol (PI) 3-kinase, which 
promotes Ca
2+
 release.  PI 3-kinase thus links PAR1 to changes in cytoskeletal structure, cell 
motility, survival and mitogenesis.  
There has been considerable interest in understanding the mechanism by which PAR1 
couples to the MAP kinase cascades given the important mitogenic role of thrombin.  Many 
data about PAR1-mediated ERK1/2 activation derive from studies in astrocytes since PAR1 
stimulate astrocytes proliferation both in vitro and in vivo.  PAR1 induces robust ERK1/2 
activation, an important mediator of astrocyte proliferation.  In contrast to transient ERK1/2 
activation induced by many stimuli, activated PAR1 causes sustained ERK1/2 signaling in 
astrocytes (Nicole et al., 2005; Suo et al., 2003).  PAR1 stimulation causes the activation of 
transcriptional factor nuclear factor κB in endothelial cells. 
PARs, like other GPCRs, can exhibit biased signaling (Rajagopal et al., 2011; Kenakin 
and Miller, 2010).  For example, the activation of PAR1 with a peptide agonist can cause 
signaling preferentially via Gq, whereas thrombin-triggered PAR1 signaling is preferentially 
coupled to G12/13 (McLaughlin et al., 2005).  Furthermore signaling via PAR1 and PAR2 can 
differ depending on receptor location with caveole localization of PAR1 being required for 
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protease-selective signaling (Russo et al., 2009).  Finally, it is important to mention, that 
activated PARs also interact with various adaptor proteins that facilitate signal transduction 
independent of heterotrimeric G protein coupling.  Among these proteins, the multifaceted -
arrestins play a major role controlling magnitude and duration of mainly PAR2- but also 
PAR1-mediated G protein signaling as well as PAR2 signaling to non-G protein effectors 
(Chen et al., 2004; Soh et al., 2010).  
 
 
1.3 Termination of the signal 
1.3.1 Disablement of PARs by cell-surface proteolysis 
 
Proteases that remove or destroy the tethered ligand or cleave the binding domain in the 
extracellular loop II would generate receptors that are unresponsive to activating proteases.  
Many proteases can disable PARs in this manner.  Disabling proteases may serve to dampen 
signalling by activating proteases and could thereby be an additional mechanism for 
terminating protease signalling.  A portion of proteolytically activated PAR1 can recycle to 
the cell surface in some cell types, although it is usually targeted for degradation.  
Proteolytically activated and recycled PAR1 can continue to signal at the cell surface (Trejo et 
al., 1998).  In this case, proteases that cleave or remove the exposed tethered ligand would 
arrest signalling.  Proteases from inflammatory cells, including neutrophils and mast cells, can 
cleave and disable PARs.  Neutrophil cathepsin G, elastase and protease 3 cleave PAR1 
removing the activation site and thereby abolish thrombin signalling (Renesto et al., 1997).  
PAR1-AP still signals to cells exposed to these proteases, suggesting that the binding domain 
is preserved.  Elastase and cathepsin G cleave PAR2 and PAR3 in transfected cells removing 
the amino-terminal epitopes and thereby generating receptors that are unresponsive to trypsin 
  CHAPTER 1 
12 
 
and thrombin, respectively.  However, PAR2 maintains its responsiveness to PAR2-AP (Dulon 
et al., 2003).  Interestingly, this process of inactivation occurs without the loss of binding of 
monoclonal antibodies that recognize sites flanking the tethered ligand domain suggesting 
inactivation does not involve removal of the tethered ligand.  The mechanism of this 
inactivation is unknown but could involve cleavage of tethered ligand binding domains.  
Some proteases can cleave PARs at several sites, including activation and disabling sites, and 
the net result depends on the efficiency of cleavage at different locations.  Although trypsin 
has been reported to activate PAR1, it also efficiently cleaves PAR1 at distal sites that would 
remove the tethered ligand domain.  Indeed, in endothelial cells, trypsin inactivates PAR1, 
generating a receptor that is unresponsive to thrombin (Nakayama et al., 2003).  In addition to 
cleavage at the activation site (Arg
34
-Ser
35
), tryptase also cleaves PAR2 at the Lys
41
-Val
42
 site, 
which could inactivate the receptor.  In the case of tryptase, the activating cleavage is more 
important since tryptase activates PAR2.  The consequences of exposing cells to proteases 
depend on the repertoire of PARs expressed by a cell and whether the proteases activate or 
disable particular receptors.  For example, cathepsin G disables PAR1 but activates PAR4.  
Thus in human platelets, which express PAR1 and PAR4, cathepsin G can induce aggregation 
through PAR4 even though it disables PAR1 and thereby prevents signalling by low 
concentrations of thrombin. In contrast, in fibroblasts and endothelial cells that do not express 
PAR4, cathepsin G abolishes thrombin signalling through PAR1.  In addition, proteolysis can 
impair the ability of PAR3 to act as a cofactor for PAR4 (Cumashi et al., 2001).  In murine 
platelets, PAR3 binds thrombin but does not signal.  Instead, it concentrates thrombin in the 
vicinity of PAR4 and thus serves as cofactor for PAR4 signaling in response to low 
concentrations of thrombin.  Cathepsin G does not cause aggregation of murine platelets but 
prevents aggregation to low concentrations of thrombin, indicating that cathepsin G abolishes 
this cofactor role of PAR3 (Ossovskaya and Bunnett, 2004). 
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1.3.2 Receptor desensitization 
  
Proteases activate PARs by an irreversible mechanism: cleavage exposes the tethered 
ligand domain that is always available to interact with the cleaved receptor.  This activation 
would result in prolonged signalling unless there were efficient mechanisms to attenuate the 
response.  The principal mechanism that terminates signalling by PARs is broadly similar to 
the classical pathway of desensitization that has been described in detail for many other 
GPCRs, in particular rhodopsin and the β2-adrenergic receptor (Bohm et al., 1997; Luttrell 
and Lefkowitz, 2002). 
Ligand occupation of the GPCR induces the translocation of members of the family of 
G protein receptor kinases (GRKs) from the cytosol to the activated receptor at the cell 
surface.  GRKs are serine-threonine kinases that phosphorylate activated GPCRs usually 
within the carboxy terminus or third intracellular loop.  Phosphorylation triggers the 
membrane translocation of arrestins, which interact with the phosphorylated transduction.  
Additional mechanism may involve phosphorylation by second messenger kinases, which 
also terminate signalling.  However, there are still many critical aspects of GPCRs 
desensitization, including PARs, which are unexplored.  Several observations suggest that 
modifications of the tethered ligand domain of cleaved PAR1 may also contribute to 
desensitization.  One mechanism may involve cleavage of the tethered ligand domain.  The 
hypothesis is that after activation with AP, the tethered ligand domain is proteolytically 
destroyed, rendering the receptor unresponsive to thrombin but not AP.  PAR4 has slow 
kinetics of desensitization that permits it to signal in a sustained fashion in human platelets.  
However, mechanisms of desensitization vary between different PARs, probably due to 
structural differences, especially in the intracellular loop III and carboxy terminus (Traynelis 
and Trejo, 2007).  
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1.3.3 Downregulation by intracellular proteases 
 
In addition to processes that regulate coupling of receptors to signalling pathways, cells 
also determine their responsiveness to agonists by regulating the levels of receptors that are 
expressed at the plasma membrane and which are thus accessible to agonists in the 
extracellular fluid.  The level of expression of receptors at the cell surface is a balance 
between removal by endocytosis and replenishment by recycling or mobilization of 
intracellular pools.  Many receptors internalize after binding agonists.  However, the fate of 
endocytosed receptors depends on postendocytic sorting, which varies from receptor to 
receptor.  At one extreme, some GPCRs that are activated in a reversible fashion by agonist 
binding, for instance the neurokinin-1 receptor, efficiently recycle to the plasma membrane to 
be reused by the cell (Defea et al., 2000).  At the other extreme, receptors such as the PARs, 
which, once cleaved, cannot be reused by the cell, are destined for intracellular degradation, 
which irrevocably terminates signalling.  For these receptors, recovery requires synthesis or 
mobilization of new receptors.  Of course, all surface receptors have a finite life span and 
even recycling receptors are downregulated by intracellular degradation after long-term 
stimulation. 
The process of receptor downregulation is of considerable importance because defects 
can result in exaggerated signalling and abnormal phenotypes, for example, transformation in 
the case of EGF receptors that are not downregulated.  PARs are an ideal model to study these 
postendocytic sorting events since they are invariably targeted for degradation after 
activation.  The molecular mechanism and pathways of agonist-induced trafficking of PARs 
vary from receptor to receptor and in different cells.  The newly synthesized PAR1 contains a 
signal peptide which targets the receptor to the plasma membrane.  
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PAR1 expressed on the plasma membrane is then subjected to two distinct modes of 
internalization: the constitutive internalization and the agonist-triggered internalization.  The 
stimulation of PAR1 with either thrombin or agonist peptides triggers the internalization of 
PAR1.  The internalized receptors are mainly targeted to lysosomal degradation and partly 
recycled to the plasma membrane (Trejo, 2003).  Internalization and lysosomal sorting of 
proteolytically activated PAR1 is thought to prevent the receptor from returning to the cell 
surface with its tethered ligand intact and continuing to signal (Trejo and Coughlin, 1999).  
Proteolysis or truncation of the tethered ligand may also occur to prevent further PAR1 
signaling.  The full recovery of the responsiveness to protease activation requires either de 
novo synthesis or the recruitment of intact receptors from the intracellular pool.  The 
importance of these mechanisms depends on whether cells possess prominent intracellular 
stores of PAR1 in the Golgi apparatus.  Platelets, which lack both the ability to synthesize new 
receptors and prominent intracellular pools, are unable to repopulate the plasma membrane 
with new receptors after thrombin exposure and thus do not recover responsiveness to 
thrombin.  Because platelets are only required to respond once to thrombin, by aggregation, 
the lack of a robust system of resensitization does not impair their function.  Moreover, 
human platelets also express PAR4, which facilitates prolonged signalling by thrombin.  
Similar mechanisms account for the resensitization of PAR2 suggesting that these are 
widespread mechanisms (Hamilton et al., 1999). 
Constitutive internalization takes place under resting conditions without any receptor 
stimulation and requires residues of the C-terminus of PAR1, which are distinct from those 
required for agonist-triggered internalization.  The cells expressing mutant PAR1, which has 
been shown to be defective in constitutive internalization but not in agonist-triggered 
internalization, are missing the intracellular pool (Shapiro et al., 1998).  The nascent PAR1 is 
thus considered to target first the plasma membrane and then be internalized into the 
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intracellular pool.  Next, the PAR1 cycles between the plasma membrane and the intracellular 
pool under resting conditions.  Therefore, the major steps that regulate the level of PAR1 
expressed on the cell surface are transcription, constitutive and agonist-triggered 
internalization, the recruitment of intact receptors from the intracellular pool and lysosomal 
degradation (Hirano et al., 2005). 
PAR1 and PAR2 are rapidly and extensively internalized after activation and the initial 
accumulation of the receptors into coated pits suggests that internalization proceeds by a 
clathrin-mediated process.  β-arrestins play a major role in endocytosis of many GPCRs by 
serving as adaptor proteins that link GRK-phosphorylated receptors to clathrin and clathrin 
adaptor protein-2 (AP2).  However, β-arrestin play no role in stimulated endocytosis of PAR1 
while it is required for PAR2 internalization.  Although the molecular mechanisms that target 
PAR2 for degradation are unknown, PAR2 is extensively ubiquitinated after activation and 
ubiquitination of some other GPCRs is a prerequisite for degradation (Traynelis and Trejo, 
2007). 
 
 
1.4 Physiology and pathophysiology of Protease Activated Receptors 
 
PARs have multiple roles in many physiological and pathological events involving 
different tissues and organs such as the cardiovascular, musculoskeletal, gastrointestinal, 
respiratory and central nervous system (CNS) (Ramachandran et al., 2012).  In addition, 
coagulant protease and PARs have been implicate in several types of malignant cancer.  PAR1 
is overexpressed in aggressive melanoma (Tellez and Bar-Eli, 2003), colon cancer (Darmoul 
et al., 2003), prostate cancer (Chay et al., 2002) and invasive breast cancer (Even-Ram et al., 
1998).  Since PARs mediate the mitogenic action of both thrombin and trypsin they can 
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regulate tumor cell growth.  Indeed, PAR1 can promote tumor cell invasion and epithelial cell 
malignancy (Even-Ram et al., 1998; Even-Ram et al., 2001; Bar-Shavit et al., 2011).  The 
expression of PAR1 and PAR2 is also increased in stromal fibroblasts of malignant tissues as 
compared to normal tissues (D’Andrea et al., 2001).  In addition, several different proteases 
which can potentially activate PAR1 and/or PAR2 have been identified in tumors including 
tissue-derived trypsins, members of the coagulation cascade and matrix metalloprotease-1 
(MMP-1) (Arora et al., 2007; Ramachandran et al., 2012).  The mitogenic activity induced by 
PAR1 or PAR2 stimulation is associated with prolonged ERK1/2 activation (Arora et al., 
2007).  Activated PAR1 also fails to be downregulated in highly invasive breast carcinoma, 
and consequently PAR1 persistently activates ERK1/2 and induce cellular proliferation and 
invasion (Booden et al., 2004).  Therefore, increased PAR1 levels in invasive carcinoma cells 
may be due, at least partially, to a defective trafficking.  Of course, other mechanisms 
contributing to increased PAR1 mRNA and protein levels are also possible such as changes in 
gene transcription (Arora et al., 2007; Bar-Shavit et al., 2011).  For example, Tellez et al. 
(2003) have demonstrated an inverse correlation between the expression of activator protein-
2 (AP2) and the overexpression of PAR1 in metastatic melanoma cells. 
 
 
1.5 Aims of the study 
 
Malignant pleural mesothelioma (MM) is a relatively rare but aggressive neoplasm 
which is associated with occupational exposure to asbestos.  Most patients are diagnosed at a 
late stage, which makes curative resection difficult.  Despite aggressive treatment with 
radiotherapy and/or chemotherapy the prognosis is poor with a median survival time between 
8 and 18 months.  MM patients are very susceptible to thromboembolic complications 
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(Nguyen et al., 2008) which can develop as a consequence of the activating effect of 
malignant cells on the haemostatic system (Noble and Pasi, 2010).  
The aim of this study was to investigate PAR1 expression levels, signaling and 
mitogenic effects in nonmalignant mesothelial (Met-5A) and MM cells (NCI-H28).  In this 
MM cell line, a homozygous deletion of the -catenin gene (CTNNB1) has been 
demonstrated (Shigemitsu et al., 2001) while thrombomodulin (TM), a natural anticoagulant, 
appears to be silenced by an epigenetic mechanism (Nocchi et al., 2011).  Therefore, we 
considered quite intriguing to study PAR1 expression and signaling in this cell line and 
correlate our findings to the known genetic and epigenetic alterations.  Our study indicates 
that the expression levels of both PAR1 mRNA and protein are increased in NCI-H28 cells 
but more important, receptor signaling to down-stream effectors is rather dysfunctional.  In 
fact, the only signaling pathway which is fully maintained is that through Gi proteins while 
those through G12/13 and Gq are either reduced or abolished.  Whereas the lack of 
thrombomodulin on plasmamembrane can alter PAR1 activation the -catenin deficiency on 
the E-cadherin/catenin complexes at cell junctions can interfere with caveolin-1 localization 
and consequently with PAR1 localization and proper signaling to Gq and G12/13. 
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MATERIALS AND METHODS 
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2.1 Materials 
 
Penicillin, streptomycin, hydrocortisone, cAMP, Ro 20-1724, protease inhibitor 
cocktail, isoproterenol and secondary antibodies were products of Sigma-Aldrich Inc. (St. 
Louis, MO); while [
3
H]-cAMP (specific activity 31.0 Ci mmol
-1
) and enhanced 
chemiluminescence substrate (Western lightning® Plus-ECL) were from PerkinElmer Inc. 
(Waltham, MA).  HMEC-1 cells were a generous gift of Dr E Ades (Centers for Disease 
Control, Atlanta, GA).  NCI-H28 and Met-5A cells were purchased from LGC Standards s.r.l. 
(Middlesex, UK).  MCDB-131 medium, Medium 199, RPMI-1640, Fetal Bovine Serum 
(FBS), trypsin-EDTA, epidermal growth factor (EGF), L-glutamine, human recombinant 
insulin, nitrocellulose membrane, Fluo-3 and Pluronic were purchased from Life 
Technologies Corporation (Paisley, UK).  WST-1 was a product of La Roche (Basel, 
Switzerland).  RhoA activation assay kit was obtained from Cytoskeleton, Inc. (Denver, CO).  
PAR1-AP (TFLLR-NH2), a selective PAR2-AP (2-furoyl-LIGRLO-NH2) and SCH79797 were 
products of Tocris Bioscience (Bristol, UK).  GB83 was purchased from Axon Medchem BV 
(Groningen, The Netherlands).  Human thrombin (high activity, ≥2800 NIH U mg-1 protein) 
was a product of Calbiochem-Novabiochem Corp. (San Diego, CA).  The RNeasy Mini Kit 
and SYBR Green PCR Kit were purchased from Qiagen GMbH (Hilden, Germany).  The Rev 
Transcription Kit was a product of New England BioLabs (Ipswich, MA).  Primary antibodies 
were from Santa Cruz Biotechnology Inc (Santa Cruz, CA).  Other agents and reagents were 
from standard commercial sources and were of the highest grade available. 
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2.2 Cell cultures  
 
In the present study human dermal microvascular endothelial cells (HMECs-1) that 
were transformed using SV-40 were used as reference cells which endogenously express 
PARs (Asteriti et al., 2012).  These cells were used to analyze the differential activation of 
signaling pathways by different PAR1-activating peptides (PAR1-APs) and to test the effects 
of modulators on signaling.   
HMECs-1 were cultured in MCDB-131 medium, supplemented with 5% FBS, 1% 
penicillin/streptomycin (100 units/ml; 100 µg/ml), hydrocortisone (1 µg/ml), epidermal 
growth factor (0.01 µg/ml) and L-glutamine (2 mM) in atmosphere of 95% air, 5% CO2 at 
37°C.  The cells were seeded at 1 x 10
5
 cells/ml in 75 ml cell culture flasks coated with 1% 
gelatin and subcultured after detachment with 0.05% trypsin, 0.5 mM EDTA.  In all 
experiments, cells were used at passages 16-20. 
Malignant mesothelioma cells (NCI-H28) and nonmalignant mesothelial cells (Met-5A) 
were used to analyze the differential activation of signaling pathways by thrombin and 
different PAR-activating peptides (PAR-APs). 
Met-5A cells were cultured in Medium 199 supplemented with 10% FBS, 1% 
penicillin/streptomycin (100 units/ml; 100 µg/ml), hydrocortisone (400 nM), epidermal 
growth factor (3.3 nM) and human recombinant insulin (870 nM) in atmosphere of 95% air, 
5% CO2 at 37°C.  In all experiments, cells were used at passages 3-9. 
NCI-H28 cells were cultured in RPMI-1640 medium, with 10% FBS and 1% 
penicillin/streptomycin (100 units/ml; 100 µg/ml), in atmosphere of 95% air, 5% CO2 at 
37°C.  The cells were seeded in 75 ml cell culture flasks and subcultured after detachment 
with 0.05% trypsin, 0.5 mM EDTA.  In all experiments, cells were used at passages 3-15. 
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2.3 Real time RT-PCR 
 
PCR (polymerase chain reaction) was used to verify the expression of PAR1 and PAR2 
mRNAs in Met-5A and NCI-H28 cells.  Total RNA was isolated from cells using the RNeasy 
Mini Kit (Qiagen).  Cells were lysed and homogenized in the presence of a highly 
denaturating buffer and the sample was then applied to an RNeasy Mini spin column, where 
the total RNAs bound to the membrane and contaminants were efficiently washed away.  
High-quality RNAs were then eluted in water.  Six microliters of total RNA for each sample 
were reverse transcribed to cDNA using a specific Rev Transcription Kit (BioLabs).  
Afterwards, three microliters cDNA were amplified with SYBR Green by specific 
oligonucleotide primers for PAR1 and PAR2 cDNA sequences, as follow: 
 
 
  
 
 
 
PAR1 primers were chosen to amplify a product of the expected size of 206 bp, while 
for PAR2 a set of primers to amplify a product of 223 bp was used. 
PCR was performed for 35 cycles with the following conditions: after initial Taq 
activation at 94°C for 5 min, each cycle consisted of denaturing at 95°C for 1 min, annealing 
at 50°C for 30 sec and extension at 72°C for 1 min, with a final elongation at 72°C for 7 min. 
The relative expression of PAR1 and PAR2, with β-actin as the reference gene, was 
determined by using the MiniOpticon™ Real-Time PCR Detection System (BioRad).  Data 
were expressed as expression ratios normalized to β-actin. 
PAR1 Forward: 5’-TGC TTC AGT CTG TGC GG-3’ 
Reverse: 5’-CTC CAT CAA TAA AAG CAG TCC TCT-3’ 
PAR2 Forward: 5’-AGC TCT GAG TTT CGA ATC GG-3’ 
Reverse: 5’-ACT CCT TTT CCA GTG ACG TG-3’ 
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2.4 SDS-PAGE and Western Blot Analysis 
 
Met-5A and NCI-H28 cells were grown in 150 mm Petri dishes, cultured until 
confluence and then serum-starved overnight at 37°C.  After incubation, cells were washed 
twice with ice-cold PBS (8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4, 137 mM NaCl and 2.7 
mM KCl) and lysed in modified RIPA buffer (PBS, pH 7.4, 1% Igepal, 0.5% sodium 
deoxycholate, 0.1% SDS and 10 l/ml protease inhibitor cocktail).  Cells were lysed for 1 h at 
4°C, then were centrifuged at 14 000 x g in a pre-cooled centrifuge for 45 min.  The 
supernatant was immediately transferred to a fresh centrifuge tube and the pellet was 
discarded.  To measure the total protein content, the Bio-Rad DC protein assay was used 
following the manufacturer’s instructions.  BSA was used as standard.  
Solubilized proteins (30 g) of each sample (Met-5A and NCI-H28) were treated with 
Laemmli solution, and then resolved by 12% SDS-PAGE gels using 20 mA for gel (Tetra cell 
apparatus, Biorad).  Proteins were then transferred onto nitrocellulose membranes (0.2 µm) 
using 100 V for 30min.  Non-specific binding was prevented by blocking the membranes with 
3% low fat dried milk, 0.2% (v/v) Tween-20 in PBS (10 mM NaH2PO4, pH 7.4, 0.9% NaCl) 
(PBS/milk/Tween) for 1 h at room temperature.  Subsequentially, nitrocelluloses were probed 
overnight at 4°C in blocking buffer with a rabbit anti-PAR1 polyclonal antibody (1:200) or a 
rabbit anti-PAR2 (1:200) polyclonal antibody.  Following three 5 minutes washes with 
PBS/milk/Tween, the immunocomplexes were detected using a peroxidase-labelled secondary 
antibody (goat anti-rabbit, 1:10 000 dilution for PAR1 and 1:20 000 dilution for PAR2).  The 
washing step was repeated as described above, followed by two washes with PBS and one 
with distilled water.  The immunoblot signal was visualized by using enhanced 
chemiluminescence substrate detection system (Western Lightning® Plus-ECL).  The 
chemiluminescent images were acquired by LAS4010 (GE Health Care).  The intensity of 
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immunoreactive bands was estimated from optical density measurements of scanned images 
using Image J (NIH, Bethesda, MD), a public domain JAVA image-processing program.  
Band optical density values were normalized by the value of total protein loaded on each well.  
Each nitrocellulose membrane probed with anti-PAR1 or anti-PAR2 antibodies was 
stripped and re-probed with a mouse anti--actin monoclonal antibody (1:2000) for 2 h at 
room temperature followed by an anti-mouse peroxidase-labelled secondary antibody 
(1:2000). 
 
 
2.5 WST-1 cell proliferation assay 
 
The assay was based on the enzymatic cleavage of the tetrazolium salt WST-1 (4-[3-(4-
Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) (from Roche) to 
colored formazan by cellular mitochondrial dehydrogenases present in viable cells.  
 
Figure. Cleavage of the tetrazolium salt WST-1 to formazan. (EC = electron coupling reagent. RS = 
mitochondrial succinate-tetrazolium-reductase system). 
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An expansion in the number of viable cells results in an increase in the overall activity 
of mitochondrial dehydrogenases in the sample.  This augmentation in enzyme activity leads 
to an increase in the amount of formazan dye formed, which directly correlates to the number 
of metabolically active cells in the culture. 
Cells were seeded in a clear 96-well plate at a density of 3 x 10
3
 cells/well in 100 µl of 
culture medium.  Cells were cultured in the incubator at 37°C and allowed to adhere 
overnight, then cells were serum starved for 12 hours and stimulated with the agonist for 24 
or 72 hours.  After that, 10 µl of WST-1 mixture were added to each well, mixed gently for 
one minute on a shaker and cells were incubated for two hours at 37°C in a CO2 incubator.  
Finally, the formazan dye, produced by metabolically active cells, was quantified by 
measuring the absorbance of each sample against a background control as blank with a 
Wallac 1420 multilabel counter microplate reader (PerkinElmer, Inc., Boston, MA) at a 
wavelength of 450 nm. 
 
 
2.6 [Ca
2+
]i measurement 
 
PAR1-mediated activation of Gq pathway was assessed by measuring the increase of 
fluorescence after agonist stimulation of cells loaded with the Fluo-3 acetoxy methylester 
(Fluo-3-AM), using a Wallac 1420 multilabel counter microplate reader (PerkinElmer, Inc., 
Boston, MA).   Fluo-3 exhibits large fluorescence intensity increases on Ca
2+
 binding.  
Cells were seeded in black/clear bottom 96-well assay plates at a density of 2 x 10
4
 
cells/well (HMEC-1) or 1.5 x 10
4
 cells/well (Met-5A and NCI-H28) in complete growth 
medium. After attachment they were starved in serum free medium containing bovine serum 
albumin (BSA) for 3 h at 37°C.  Before starting the assay, cells were washed twice with 
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loading buffer (20 mM Hepes, 0.83 mM Na2HPO4, 0.17 mM NaH2PO4, pH 7.4, + 130 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, and 1 mM MgSO4) containing 25 mM mannose, 1 mg/ml 
BSA and 2.5 mM probenecid and then incubated in 100 µl of the same buffer containing 6 
µM Fluo-3-AM/0.024% pluronic acid.  The fluorescent probe can penetrate the cells by the 
presence of the ester, which is subsequently hydrolyzed by intracellular esterases to an active 
form.  The presence of probenecid further reduce any possible leak of Fluo-3 from the cells, 
since it is a standard inhibitor of nonspecific organic anion carrier.  After 1 h at 37°C, cells 
were washed two times with loading buffer and incubated in 100 µl of the same buffer for an 
additional 1 h at 37°C to remove any excess of dye.  Fluorescence measurements, reflecting 
the increase of [Ca
2+
]i, were carried out at 37°C with an excitation wavelength of 480 nm and 
emission recorded at 530 nm.  Fluorescence was recorded at baseline and then every 3 
seconds after thrombin (50 nM) or PAR-AP (10 M) addition for another 120 seconds.  The 
data were expressed as fluorescence ratios. 
Whereas the selective PAR1- and PAR2-APs were purchased from Tocris as mentioned 
in Materials the nonselctive PAR1-AP was synthesized in Dr. A.M. D’Ursi’s laboratory 
(Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno). 
 
PAR-AP sequences 
Peptides Sequence 
Selective PAR1-AP (Tocris) TFLLRN-NH2 
Selective PAR2-AP (Tocris) 2-furoyl-LIGRLO-NH2 
PAR1-AP SFLLRN-NH2 
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2.7 RhoA activation 
 
Cells were seeded in 150 mm dishes until 60% confluence and serum-starved for 18 
hours.  Cells were then stimulated with 10 nM thrombin for zero and two minutes.  After that, 
culture dishes were placed on ice and washed with ice cold PBS.  Then, cells were lysed with 
500 µl ice-cold cell lysis buffer supplemented with protease inhibitors.  Lysates were 
transferred into a tube and centrifuged at 10,000 g for  3 minutes at 4°C.  Afterwards, cell 
lysates were added to a 96 well plate (RhoA G-LISA® kit from Cytoskeleton) that contained 
a Rho-GTP-binding protein linked to the wells.  Active, GTP-bound Rho in cell lysates bound 
to the wells while inactive GDP-bound Rho was removed during washing steps.  The bound 
active RhoA was detected with a RhoA specific antibody.  The degree of RhoA activation 
was determined by comparing readings from activated cell lysates versus non-activated cell 
lysates.  Inactivation of RhoA was generally achieved in cell culture by the serum starvation 
step.  Finally, the absorbance of each sample was measured by using a Wallac 1420 multilabel 
counter microplate reader (PerkinElmer, Inc., Boston, MA) at a wavelength of 490 nm and 
results were expressed as absorbance ratios. 
 
 
2.8 Measurement of intracellular cAMP 
 
Intracellular cAMP levels were measured using a competitive protein binding method. 
Cells (4 x 10
4
/well) were plated in 24-well plates in 0.5 ml of medium.  After 24 h, the 
medium was removed and 0.5 ml of serum free medium with phosphodiesterase inhibitor, Ro 
20-1724 (20 µM), was added and the cells incubated at 37°C for 15 min.  Cells were then 
exposed to different thrombin and peptide concentrations ranging from 100 nM to 10 µM (15 
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min at 37°C).  Assays were initiated by the addition of 1 µM isoproterenol.  The reaction was 
terminated by the removal of the medium and the addition of 0.4 N HCl.  After 30 min, 
lysates were neutralized with 4 N KOH, and the suspension centrifuged at 800 x g for 5 
minutes.  To measure cAMP production, bovine adrenal cAMP binding protein was incubated 
with [
3
H]cAMP (2 nM) and 50 µl of cell lysates or cAMP standard at 0°C for 150 min in a 
total volume of 300 µl.  Bound radioactivity was separated by rapid filtration through GF/C 
glass fiber filter using a cell harvester.  The radioactivity was measured by liquid scintillation 
spectrometry. 
 
 
2.9 Data Analysis 
 
Data analysis were performed by the computer program GraphPad Prism for Windows 
(GraphPad Software, San Diego, CA).  Values represent the means ± S.E.M. of at least three 
independent experiments.  The statistical significance of value differences was evaluated by 
ANOVA test followed by Bonferroni’s multiple comparison test using GraphPad Prism for 
Windows.  
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RESULTS 
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PARs and their potential activating proteases are frequently overexpressed in human 
tumor tissues, including prostate and colon cancer as well as malignant melanoma (Arora et 
al., 2007; Bar-Shavit et al., 2011; Ramachandran et al., 2012).   Lee et al. (2005) have shown 
that PAR2 is present in human pleural tissues where it plays a role in pleural inflammatory 
responses while in primary cultures of human peritoneal mesothelial cells the expression of 
PAR1 has been reported (Belling et al., 2013).  Therefore, we decided to investigate 
expression and signaling of PARs in human pleural mesothelial and MM cells to evaluate the 
role of these receptors in mesothelioma cell proliferation and survival.  As first step of this 
study, the MM cell line NCI-H28 which does not express CXCR4 (Li et al., 2011), was used 
while the nonmalignant mesothelial cell line Met-5A was utilized as control.  In this MM cell 
line, apart from a homozygous deletion of the β-catenin gene (CTNNB1) (Shigemitsu et al., 
2001) a down-regulation of thrombomodulin expression by an epigenetic mechanism has 
been described (Nocchi et al., 2011).  The expression of thrombomodulin, a glycosilated 
transmembrane protein which binds with high affinity thrombin inhibiting its enzymatic 
activity and accelerating protein C activation, is lower in MM tissue than in normal 
mesothelium (Nocchi et al., 2011).  In addition, low or no expression of the protein in various 
cancers has been associated with poor prognosis (Matsushita et al., 1998; Ogawa et al., 2000; 
Liu et al., 2010). 
To verify whether PAR1 and PAR2 mRNA levels were different in NCI-H28 cells as 
compared to those in Met-5A cells, real time RT-PCR was performed using RNA extracted 
from MM and nonmalignant control cells, respectively.  In NCI-H28 cells, PAR1 mRNA level 
was approximately 3-fold higher than in Met-5A cells while PAR2 mRNA amount was 
slightly reduced in MM cells as compared to nonmalignat control cells (Fig. 1, panel A).  
Similarly, immunoblot analysis showed that in NCI-H28 cells the expression level of PAR1 
was significantly increased as compared to Met-5A cells while PAR2 expression was 
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substantially unchanged in MM cells (Fig. 1, panel B).  These results indicate that the 
increased expression of PAR1 in NCI-H28 is mainly dependent by an increase of gene 
transcription and/or modification of PAR1 mRNA stability. 
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Figure 1. Detection of PAR mRNA (panel A) and protein levels (panel B) by real time RT-PCR and western 
blot analysis, respectively, in Met-5A and NCI-H28 cells. Data are normalized to β-actin. Data shown are mean 
± SEM of at least three independent experiments. Values that are significantly different from control value (* 
p<0.05; ** p<0.01; *** p<0.001), as determined by ANOVA followed by Bonferroni’s multiple comparison test, 
are indicated. 
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Next, we examined whether in the MM cell line PAR1 was functionally active by 
evaluating thrombin- or PAR-APs-induced cell proliferation.  After 72 h from thrombin 
stimulation, both Met-5A and NCI-H28 cells showed significant increase of cell proliferation 
(Fig. 2).  However, the pattern of the proliferative response was quite different in MM cells as 
compared to that of nonmalignant mesothelial cells.  In fact, in Met-5A the proliferative 
response was maximal at 1 nM thrombin with a progressive decrease up to 50 nM while in 
NCI-H28 cells the maximal response was reached at 50 nM (Fig. 2). 
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Figure 2. Thrombin-induced proliferation of Met-5A and NCI-H28 cells. Cells were seeded at a density of 3 x 
10
3
 cells/well and stimulated with the agonist for 24 or 72 hours. Data shown are mean ± SEM of at least three 
independent experiments. Values that are significantly different from control value (* p<0.05; ** p<0.01; *** 
p<0.001) and from the reference value in Met-5A (
#
 p<0.05; 
##
 p<0.01; 
###
 p<0.001), as determined by ANOVA 
followed by Bonferroni’s multiple comparison test, are indicated. 
 
 
The non-selective PAR1-AP, SFLLRN-NH2, was less effective than thrombin in 
stimulating Met-5A and NCI-H28 cell proliferation (Fig. 3, panel A).  A 24 – 28% increase of 
cell proliferation was reached at 10 and 100 µM SFLLRN-NH2 in Met-5A and NCI-H28 
cells, respectively (Fig. 3, panel A).  The selective PAR1-AP, TFLLR-NH2, was less effective 
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in stimulating Met-5A cell proliferation than SFLLRN-NH2 but a concentration of 100 µM 
caused a 20% increase of NCI-H28 cell proliferation (Fig. 3, panel B).  To evaluate the role of 
PAR2 in stimulating mesothelial cell proliferation, both cell lines were stimulated with a 
selective PAR2-AP, 2-furoyl-LIGRLO-NH2.  Treatment of Met-5A cells with the selective 
PAR2-AP caused inhibition of cell proliferation while in NCI-H28 cells 10 and 100 µM 2-
furoyl-LIGRLO-NH2 induced approximately 20% increase of cell proliferation (Fig. 3, panel 
C).  These results point out that PAR-APs do not behave as thrombin in activating PAR 
signaling.  Furthermore, both PAR1 and PAR2 signaling appears to be quite different in NCI-
H28 as compared to receptor signaling in Met-5A cells. 
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Figure 3. Non-selective PAR1-AP- (panel A), selective PAR1-AP- (panel B) and selective PAR2-AP-induced 
(panel C) proliferation of Met-5A and NCI-H28 cells. Cells were seeded at a density of 3 x 10
3
 cells/well and 
stimulated with the agonist for 72 hours. Data shown are mean ± SEM of at least three independent experiments. 
Values that are significantly different from control value (* p<0.05; ** p<0.01; *** p<0.001) and from the 
reference value in Met-5A (
#
 p<0.05; 
##
 p<0.01; 
###
 p<0.001), as determined by ANOVA followed by 
Bonferroni’s multiple comparison test, are indicated. 
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In order to understand whether thrombin- or SFLLRN-NH2-activated PAR1 is able to 
cross-talk and activate PAR2 as our results seem to suggest, we performed additional 
proliferation experiments using selective PAR-APs in combination, thrombin in the presence 
and absence of a PAR1 or PAR2 antagonist, or the non selective SFLLRN-NH2 peptide in the 
presence and absence of the PAR1 antagonist.  The selective PAR2 peptide inhibited in a 
concentration-dependent manner Met-5A cell proliferation reaching a 56% inhibition at 100 
µM.  In the presence of 10 µM TFLLR-NH2, the inhibition curve of 2-furoyl-LIGRLO-NH2 
was upwards and right shifted but reached the maximal effect (56% inhibition) at 100 µM 
(Fig. 4, panel A).  On the other hand, TFLLR-NH2 and 2-furoyl-LIGRLO-NH2 were 
synergistic in stimulating NCI-H28 cell proliferation (Fig. 4, panel B).   
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Figure 4. Effect of selective PAR2-AP on Met-5A (panel A) and NCI-H28 (panel B) cells, in presence and 
absence of PAR1-AP. Cells were seeded at a density of 3 x 10
3
 cells/well and stimulated with the agonist for 72 
hours. Data shown are mean ± SEM of at least three independent experiments. Values that are significantly 
different from control value (* p<0.05; ** p<0.01; *** p<0.001) and from the value with one peptide (
#
 p<0.05; 
##
 p<0.01; 
###
 p<0.001), as determined by ANOVA followed by Bonferroni’s multiple comparison test, are 
indicated. 
 
 
In Met-5A cells, the proliferative effect of thrombin was modestly reduced by the PAR1 
antagonist, SCH 79797 while in NCI-H28, thrombin-induced proliferation significantly 
decreased in the presence of the receptor antagonist (Fig. 5, panel A and B).    
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Figure 5. Thrombin induced proliferation of Met-5A (panel A) and NCI-H28 (panel B) cells, in the presence and 
absence of PAR1 antagonist. Cells were seeded at a density of 3 x 10
3
 cells/well and stimulated with the agonist 
for 72 hours. Data shown are mean ± SEM of at least three independent experiments. Values that are 
significantly different from control value (* p<0.05; ** p<0.01; *** p<0.001) and from the reference value in 
Met-5A (
#
 p<0.05; 
##
 p<0.01; 
###
 p<0.001), as determined by ANOVA followed by Bonferroni’s multiple 
comparison test, are indicated. 
 
Moreover, Met-5A and NCI-H28 cell proliferation induced by SFLLRN-NH2 was only 
modestly reduced in the presence of SCH 79797 (Fig. 6, panel A and B) indicating that this 
activating peptide stimulate cell proliferation through independent activation of both PAR1 
and PAR2. 
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Figure 6. Non-selective PAR1-AP induced proliferation of Met-5A (panel A) and NCI-H28 (panel B) cells, in 
the presence and absence of PAR1 antagonist. Cells were seeded at a density of 3 x 10
3
 cells/well and stimulated 
with the agonist for 72 hours. Data shown are mean ± SEM of at least three independent experiments. Values 
that are significantly different from control value (* p<0.05; ** p<0.01; *** p<0.001), as determined by 
ANOVA followed by Bonferroni’s multiple comparison test, are indicated. 
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Finally, we examined the effect of the PAR2 antagonist, GB83, on thrombin-induced 
cell proliferation.  This antagonist modified the proliferative response of neither Met-5A nor 
NCI-H28 cells (Fig. 7) suggesting that PAR1 tethered ligand does not transactivate PAR2 in 
these cells.  Moreover, these experimental evidences support the existence of altered PAR1 
and PAR2 signaling in the malignant mesothelioma cell line. 
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Figure 7. Thrombin-induced proliferation of Met-5A and NCI-H28 cells in the presence and absence of a PAR2 
antagonist. Cells were seeded at a density of 3 x 10
3
 cells/well and stimulated with the agonist for 72 hours. Data 
shown are mean ± SEM of at least three independent experiments. 
                        
 
 
In order to address this question, receptor-induced Gq, G12/13, and Gi signaling pathways 
were examined.  First, we investigated PARs-activated Gq signaling by analyzing intracellular 
Ca
2+
 mobilization after cell stimulation with either thrombin or PAR-APs.  To measure Ca
2+
 
transient, Fluo 3-AM and a Wallac 1420 multilabel counter microplate reader were utilized as 
described under Material and Methods.  As indicated by relative fluorescence increase, both 
thrombin (10 nM) and selective PAR-APs (10 µM) induced rapid and transient increase of 
[Ca
2+
]i in Met-5A as well as in microvascular endothelial cells (HMEC-1) (Fig. 8, panel A 
and B).  On the contrary, in NCI-H28 cells, thrombin- and PAR-APs-stimulation did not 
cause any rapid increase of [Ca
2+
]i (Fig. 8, panel A and B).  However, Met-5A and NCI-H28 
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showed similar expression levels of  proteins involved in this signaling pathway, such as Gαq 
and phospholipase C-β (PLC-β) isoforms (data not shown).   
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Figure 8. Intracellular Ca
2+
 mobilization induced by thrombin (panel A) and selective PAR-APs (panel B) in 
HMEC-1 (2 x 10
4
 cells/well), Met-5A (1.5 x 10
4
 cells/well) and NCI-H28 (1 x 10
4
 cells/well) cells. Cells were 
loaded with Fluo-3AM to measure [Ca
2+
]i variations as indicated by changes in fluorescence intensity. 
Fluorescence was monitored for up to 120 seconds. Data are mean ± SEM of at least three independent 
experiments and are reported as percent of maximal relative fluorescence (RF = (F – F0)/F0 where F0 is basal 
fluorescence and F is fluorescence recorded after cell stimulation with the agonist).  
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Next, we examined PARs-induced G12/13 signaling by measuring RhoA activation after 
cell stimulation with either thrombin or PAR-APs.  To detect RhoA activation the RhoA G-
LISA® kit from Cytoskeleton was used as described under Material and Methods.  In Met-5A 
cells, 10 nM thrombin induced a significant 2.5-fold increase of RhoA activation while in 
NCI-H28 cells the increase was just 1.2-fold (Fig. 9, panel A).  The selective PAR1-AP (10 
µM) was less effective in stimulating RhoA activation than thrombin in Met-5A cells but it 
still caused a significant ~2-fold increase (Fig. 9, panel B).  Similarly to thrombin, PAR1-AP 
induced a modest increase of RhoA activation in NCI-H28 cells (Fig. 9, panel B).  
Stimulation of both Met-5A and NCI-H28 cells with the selective PAR2-AP (10 µM) did not 
induce any RhoA activation (Fig. 9, panel C).  It is important to mention that in both cell lines 
the expression levels of Gα12, Gα13, and RhoA were similar (data not shown).   
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Figure 9. RhoA activation in response to thrombin (panel A), PAR1-AP (panel B) and PAR2-AP (panel C) in 
Met-5A and NCI-H28 cells. RhoA activation was measured using RhoA G-LISA® kit from Cytoskeleton. Data 
shown are mean ± SEM of at least three independent experiments. Values that are significantly different from 
control value (* p<0.05; ** p<0.01; *** p<0.001) and from the reference value in Met-5A (
#
 p<0.05; 
##
 p<0.01; 
###
 p<0.001), as determined by ANOVA followed by Bonferroni’s multiple comparison test, are indicated. 
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Finally, thrombin- and PAR-APs-induced inhibition of isoproterenol stimulated cAMP 
accumulation was examined in both Met-5A and NCI-H28 cells.  In Met-5A cells, 10 pM to 1 
nM thrombin inhibited isoproterenol stimulated cAMP production in a concentration 
dependent manner reaching 50% inhibition at 1 nM (Fig. 10, panel A).  However, at higher 
thrombin concentrations (1 nM to 100 nM) the inhibitory effect was progressively reverted.  
In the presence of the PAR1 antagonist SCH 79797 the inhibitory effect of thrombin was 
significantly reduced indicating that PAR1 mediates such effect.  In NCI-H28 cells, thrombin 
inhibited cAMP in a concentration dependent manner reaching 50% and maximal inhibition 
(~ 70%)  at 1 nM and 100 nM, respectively (Fig. 10, panel A).  In the presence of SCH 79797, 
the inhibition curve was upwards shifted and the maximal inhibition at 100 nM was only 
42%.  Various concentrations of the selective PAR-APs did not cause any inhibition of 
isoproterenol stimulated cAMP production in both Met-5A and NCI-H28 cells demonstrating 
the functional selectivity of these agonists. 
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Figure 10. Inhibition of isoproterenol stimulated cAMP production by thrombin (panel A) and selective PAR-
APs (panel B) in Met-5A and NCI-H28 cells Production of cAMP was measured using a competition binding 
assay which includes the bovine adrenal cAMP binding protein and [
3
H]cAMP. Data shown are mean ± SEM of 
at least three independent experiments. 
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PARs elicit cellular response to coagulant proteases triggered by vascular injury 
(Coughlin, 2005).  In addition, coagulant proteases and PARs have been implicated in several 
types of malignant tumors.  Indeed, a well-documented link between hyperactivation of the 
coagulation cascade and tumor progression exists.  The procoagulant activity mediated by the 
action of coagulant proteases such as thrombin can contribute to the malignant phenotype 
both directly, by stimulating tumor cell proliferation, and indirectly through the development 
of tumor-associated thromboemboli (Nierodzik and Karpatkin, 2006).  Among all cancer 
patients, MM patients are very susceptible to thromboembolic complications (Nguyen et al., 
2008).  Therefore, it seemed quite important to investigate whether a correlation exists 
between PAR expression and proliferation in a MM cell line, NCI-H28, in which 
thrombomodulin, a transmembrane glycoprotein that control thrombin-mediated proteolysis, 
is silenced by an epigenetic mechanism (Nocchi et al. 2011).  
Indeed, the proliferative response of NCI-H28 cells to various concentrations of 
thrombin is quite different than that obtained in nonmalignant mesothelial cells, Met-5A.  
Whereas in MM cells thrombin-induced proliferation rapidly increases at agonist 
concentrations ranging from 0.1 nM to 100 nM in Met-5A cells thrombin induces the 
maximal effect at 1 nM and then at higher concentrations the stimulatory effect progressively 
decrease reaching at 100 nM the basal level (Fig. 5).  Although NCI-H28 cells express higher 
amounts of PAR1, receptors respond to higher thrombin concentrations with the same level of 
proliferation than nonmalignant mesothelial cells.  However, in MM cells the proliferative 
response increases without reaching any growth steady state as expected when cells lose 
contact inhibition which is a typical characteristic of cancer cells.  In MM cells, the observed 
differences can result from alteration of the cross-talk of PAR1 with other proteins, including 
PAR2, or by the absence of thrombomodulin on cell membrane.  We addressed the former 
issue by examining PAR-APs- and thrombin-induced proliferation in the presence and 
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absence of antagonists.  The experiments with a non selective peptide, SFLLRN-NH2, which 
activate both PAR1 and PAR2 (Ramachandran et al., 2012) demonstrate that both receptors are 
able to induce a proliferative response in nonmalignant mesothelial and MM cells.  In NCI-
H28 cells, selective PAR1- and PAR2-APs show a synergistic effect but the same does not 
occur in Met-5A cells suggesting differences in the mechanism of receptor activation and/or 
signaling.  At this moment we cannot say whether in MM cells PAR2 is mutated and thus 
activation and signaling are altered.  Since the nonselective peptide stimulates proliferation in 
Met-5A as well as in NCI-H28, we are inclined towards believing the inhibitory effect of 2-
furoyl-LIGRLO-NH2 on Met-5A cell proliferation as a consequence of functional selectivity.  
This is a process reported for many GPCRs including PAR1 (McLaughlin et al., 2005; Russo 
et al., 2009) by which different ligands acting at the same receptor can elicit distinct signaling 
responses.  The molecular basis of functional selectivity involves ligand induced stabilization 
of distinct active GPCR conformation (Urban et al, 2007).  Moreover, compartmentalization 
of GPCRs within membrane microdomains seems to facilitate stabilization of distinct active 
conformations promoting receptor coupling to specific G proteins and therefore signaling 
effectors (Zheng et al., 2008).  
O’Brien et al. (2000) reported that thrombin-cleaved PAR1 transactivates PAR2 in 
human umbilical vein endothelial cells (HUVECs) thus limiting the effectiveness of PAR1 
antagonists.  We can exclude such event in both nonmalignant mesothelial and MM cells 
since the presence of a PAR2 antagonist does not modify thrombin concentration-response 
curves.  However, we do not feel to exclude the formation of heterodimeric complexes 
between PAR1 and PAR2 or even PAR3.  In both cell lines, PAR3 expression was not tested 
while PAR4 was not detectable by immunoblot analysis (data not shown).  The role of 
thrombomodulin in modulating thrombin-induced proliferative response is still an open 
question which will be addressed in future experiments of thrombomodulin silencing.   
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When PAR1-mediated activation of the single signaling pathways was examined, we 
immediately noticed that Gq and G12/13 signaling was compromised in NCI-H28 cells.  In 
addition, the selective PAR2-AP failed to mobilized intracellular Ca
2+
 in NCI-H28 cells while 
Met-5A cells respond with a 4-fold increase of relative fluorescence to the agonist, indicating 
that PAR2-mediated activation of Gq is also compromised.  Of course, we analyzed the 
expression levels of various proteins involved in these signaling pathways but all proteins 
examined showed similar levels in both cell lines (data not shown).  In NCI-H28 cells, the 
only signaling pathway which is fully activated by PAR1 is that through Gi proteins, leading 
to inhibition of adenylyl cyclase.  It is interesting to note that selective PAR-APs do not cause 
any major inhibition of cAMP accumulation.  These findings are in agreement with thrombin 
and PAR1-AP displaying functional selectivity at PAR1 as reported by McLaughlin et al. 
(2005) but they also suggest that the selective PAR2-AP, 2-furoyl-LIGRLO-NH2, stabilizes 
PAR2 in a conformation which leads to prevalent activation of Gq in nonmalignant 
mesothelial cells.   
The altered Gq and G12/13 signaling with the prevalence of Gi signaling in NCI-H28 cells 
can explain the altered proliferative response to thrombin stimulation.  Indeed, PAR1-
mediated activation of extracellular signal-regulated protein kinases 1,2 (ERK1,2) occurs 
through both Gq and Gi signaling (Trejo et al., 1996) with consequent activation of 
mitogenesis.  However, Gq signaling can be also involved in apoptosis induction and 
progression through IP3-evoked Ca
2+
 increase and signaling (Decrock et al., 2013).  This can 
explain the biphasic proliferation curve obtained after Met-5A stimulation with various 
thrombin concentrations.  On the other hand, the selective PAR2-AP which causes a prevalent 
activation of Gq in these cells induces a profound proliferation inhibition.  In the MM cell 
line, the same peptide stimulates proliferation probably through -arrestin-mediated activation 
of ERK1/2 signaling (Arora et al., 2007).  Thus, the altered signaling through Gq does not 
  CHAPTER 4 
49 
 
only involve PAR1 but also PAR2 suggesting that PARs-Gq coupling is compromised in 
NCI-H28 cells.  Whereas PAR1-G12/13 coupling is also dysfunctional in this cell line we 
cannot say much about PAR2- G12/13 coupling since the selective PAR2-AP does not induce 
any RhoA activation in the control cell line.   
The compartmentalization of PARs and G proteins in plasma membrane lipid raft 
microdomains such as caveolae may also confer PAR-G protein selectivity (Arora et al., 
2007).  For example, Russo et al. (2009) showed the critical role for caveole in activated 
protein C (APC), but not thrombin, activation of PAR1 signaling in endothelial cells.  
Furthermore, for other GPCRs several reports indicate that caveolin-1 is required to prolong 
Gq signaling (Calizo and Scarlata, 2012) and inhibits receptor coupling to Gi/o proteins (Sato 
et al., 2012).  In thrombin stimulated endothelial cells, caveolin-1 opens cell junction by 
targeting catenins (Kronstein et al., 2012).  The recruitment of caveolin-1 to cell junctions is 
greatly facilitates by the presence of -catenin in the VE-cadherin/catenin complex.  In NCI-
H28 cells, a homozygous deletion of the -catenin gene (CTNNB1) has been demonstrated 
(Shigemitsu et al., 2001) suggesting that in these cells caveolin-1 is not completely associated 
to cell membranes.  Indeed, preliminary immunofluorescence experiments show that in MM 
cells caveolin-1 is partially localized in the cytoplasm while in nonmalignant mesothelial cells 
it colocalizes with -cateninin at plasma membrane of cell junctions.  Moreover, in NCI-28 
cells, PAR1 seems to be partially localized in the cytoplasm.  Caveolin-1 may be required for 
proper membrane localization and G protein coupling of PAR1.   
In conclusion, we demonstrated that thrombin and PAR1-APs display functional 
selectivity at PAR1.  A prevalent selectivity of the PAR2-AP for Gq signaling was also showed 
for the first time.  Finally, we reported numerous evidences indicating a dysfunctional PAR1 
signaling in NCI-H28 cells which results as final consequence of the lack of -cateninin.
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